JP2005512574A5 - - Google Patents

Download PDF

Info

Publication number
JP2005512574A5
JP2005512574A5 JP2003554914A JP2003554914A JP2005512574A5 JP 2005512574 A5 JP2005512574 A5 JP 2005512574A5 JP 2003554914 A JP2003554914 A JP 2003554914A JP 2003554914 A JP2003554914 A JP 2003554914A JP 2005512574 A5 JP2005512574 A5 JP 2005512574A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
acid sequence
amino acid
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003554914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512574A (ja
Filing date
Publication date
Priority claimed from US10/027,736 external-priority patent/US6911321B2/en
Application filed filed Critical
Publication of JP2005512574A publication Critical patent/JP2005512574A/ja
Publication of JP2005512574A5 publication Critical patent/JP2005512574A5/ja
Withdrawn legal-status Critical Current

Links

JP2003554914A 2001-12-19 2002-12-03 非ヒト霊長類Fcレセプターおよびその利用方法 Withdrawn JP2005512574A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/027,736 US6911321B2 (en) 2001-12-19 2001-12-19 Non-human primate Fc receptors and methods of use
PCT/US2002/038805 WO2003054213A2 (en) 2001-12-19 2002-12-03 NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE

Publications (2)

Publication Number Publication Date
JP2005512574A JP2005512574A (ja) 2005-05-12
JP2005512574A5 true JP2005512574A5 (enExample) 2006-07-13

Family

ID=21839483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003554914A Withdrawn JP2005512574A (ja) 2001-12-19 2002-12-03 非ヒト霊長類Fcレセプターおよびその利用方法

Country Status (7)

Country Link
US (3) US6911321B2 (enExample)
EP (1) EP1456222A4 (enExample)
JP (1) JP2005512574A (enExample)
AU (1) AU2002357071A1 (enExample)
CA (1) CA2466885A1 (enExample)
IL (1) IL161543A0 (enExample)
WO (1) WO2003054213A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP3993783B2 (ja) * 2002-04-04 2007-10-17 株式会社小糸製作所 車両用灯具の設計方法、設計システム、プログラム、及び記録媒体
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
BRPI0406724A (pt) * 2003-01-13 2005-12-20 Macrogenics Inc Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) * 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CA2545603A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
ES2371468T3 (es) * 2003-11-26 2012-01-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. SUSTANCIA QUE SE UNE AL RECEPTOR HUMANO llb MEDIANTE Fc DE IgG (Fc? Rllb).
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP2053062A1 (en) * 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
WO2006076594A2 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
ME01786B (me) 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
ES2742268T3 (es) 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
JP5812627B2 (ja) * 2010-03-10 2015-11-17 公益財団法人相模中央化学研究所 改良Fc受容体およびその製造方法
US10611817B2 (en) 2013-09-18 2020-04-07 Tosoh Corporation Fc-binding protein, method for producing said protein, and antibody adsorbent using said protein, and methods for purifying and identifying antibody using said adsorbent
SMT202000332T1 (it) * 2014-04-08 2020-07-08 Regeneron Pharma Animali non umani aventi recettori fc-gamma umanizzati
CA3014466A1 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN111263813B (zh) 2017-10-27 2023-10-17 东曹株式会社 耐碱性提高的Fc结合性蛋白质及其制造方法、使用该蛋白质的抗体吸附剂和分离抗体的方法
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
WO2024232948A1 (en) * 2023-05-05 2024-11-14 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
CN116769014A (zh) * 2023-06-07 2023-09-19 河南省农业科学院动物免疫学重点实验室 一种牛IgG Fc受体boFcγRI的线性配体结合表位

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
WO1994025570A1 (en) * 1993-04-23 1994-11-10 Sloan-Kettering Institute For Cancer Research Method for screening for targets for anti-inflammatory or anti-allergic agents
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies

Similar Documents

Publication Publication Date Title
JP2005512574A5 (enExample)
ES2322945T3 (es) Metodos para la purificacion de proteina.
EP1730198B1 (en) Adzymes and uses thereof
JP5522723B2 (ja) 新規ポリペプチド,アフィニティークロマトグラフィー用材,及びイムノグロブリンの分離及び/又は精製方法
TWI598361B (zh) Cx3cr1-結合多肽
Harari et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis
AU2018390418A1 (en) Engineered IL-2 FC fusion proteins
KR20100084996A (ko) 면역글로불린 단편을 이용한 생리활성 단백질 또는 펩타이드의 생산 방법
JP2016505251A5 (enExample)
CA2905141A1 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
US20250195673A1 (en) Compositions and methods for selective depletion of target molecules
KR20170065026A (ko) 대사 장애 치료용으로 이용되는 조성물 및 방법
WO2020099871A1 (en) Single domain antibodies that bind human serum albumin
CN113227134A (zh) 抗体的Fc区变体
CN105518023A (zh) Fab区域结合性肽
KR20220131221A (ko) 바코드화된 xten 폴리펩티드 및 이의 조성물, 및 이의 제조 방법 및 사용 방법
CN113840835A (zh) 结合分子
KR20110021723A (ko) 단백질 정제 방법 및 단백질 정제용 친화성 컬럼
CN120051292A (zh) Il-18融合蛋白以及生产il-18的方法
CA3206901A1 (en) Paraoxonase fusion polypeptides and related compositions and methods
WO2023235522A1 (en) Compositions and methods for selective depletion of egfr target molecules
JP2021525807A (ja) ポリユビキチンリンカーに結合された線形多機能性マルチマー生体分子及びその用途
WO1995006737A1 (en) Glycophorin binding protein (gbp130) fusion compositions
CN100427506C (zh) 从融合多肽制备感兴趣的多肽的方法
CN102977205A (zh) 骨保护素变异蛋白